POSSIBLE CIPROFLOXACIN-INDUCED ACUTE CHOLESTATIC JAUNDICE

被引:25
作者
SHERMAN, O [1 ]
BEIZER, JL [1 ]
机构
[1] ST JOHNS UNIV,COLL PHARM & ALLIED HLTH PROFESS,DEPT CLIN PHARM,8000 UTOPIA PKWY,JAMAICA,NY 11439
关键词
D O I
10.1177/106002809402801005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of acute cholestatic jaundice in a patient who was receiving oral ciprofloxacin. CASE SUMMARY: An 84-year-old woman residing in a long-term care facility developed acute cholestatic jaundice while being treated with ciprofloxacin for a urinary tract infection. On day 6 of ciprofloxacin therapy, she was noted to have an erythematous, pruritic rash over her chest and abdomen. At this point ciprofloxacin treatment was discontinued, as an allergy was suspected. Three days later she was noted to have jaundiced sclera and skin, and liver function test results were markedly elevated. The plasma cholesterol concentration was increased substantially; there was no decrease in plasma albumin concentration or increase in prothrombin time. The patient was treated with intravenous fluids. Within the next month, the liver function test results decreased to near normal and the patient was asymptomatic. Follow-up liver test results three months later were normal. DISCUSSION: To our knowledge, there are only a few other case reports in the literature of a possible ciprofloxacin-induced liver injury. Enoxacin, a fluorinated quinolone antibiotic similar to ciprofloxacin, was reported to cause cholestatic liver injury in one patient. The exact mechanism by which fluoroquinolones may cause liver injury is unknown. CONCLUSIONS: We believe that this is only the second reported case of acute cholestatic jaundice resulting from ciprofloxacin therapy. Although this reaction seems to occur rarely, it is prudent to be alert for the signs and symptoms of cholestasis when administering ciprofloxacin.
引用
收藏
页码:1162 / 1164
页数:3
相关论文
共 13 条
[1]   ENOXACIN ACUTE LIVER-INJURY [J].
AMITRANO, L ;
GIGLIOTTI, T ;
GUARDASCIONE, MA ;
ASCIONE, A .
JOURNAL OF HEPATOLOGY, 1992, 15 (1-2) :270-270
[2]  
AMMANN R, 1982, LANCET, V2, P336
[3]   POSSIBLE CASE OF PROCAINAMIDE-INDUCED INTRAHEPATIC CHOLESTATIC JAUNDICE [J].
CHUANG, LC ;
TUNIER, AP ;
AKHTAR, N ;
LEVINE, SM .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (04) :434-437
[4]   JAUNDICE ASSOCIATED WITH CEPHALOSPORIN THERAPY [J].
EGGLESTON, SM ;
BELANDRES, MM .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (7-8) :553-555
[5]  
FRANKS E, 1975, MO MED, V72, P605
[6]   FULMINANT HEPATIC-FAILURE POSSIBLY RELATED TO CIPROFLOXACIN [J].
GRASSMICK, BK ;
LEHR, VT ;
SUNDARESON, AS .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (05) :636-639
[7]   DRUG-INDUCED HEPATOTOXICITY [J].
KAPLOWITZ, N ;
AW, TY ;
SIMON, FR ;
STOLZ, A .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :826-839
[8]  
Levinson JR, 1993, AM J GASTROENTEROL, V88, P1619
[9]  
MCEVOY GK, 1993, AHFS DRUG INFORMATIO, P1412
[10]   SAFETY OF ORAL CIPROFLOXACIN - AN UPDATE BASED ON CLINICAL-TRIAL RESULTS [J].
SCHACHT, P ;
ARCIERI, G ;
HULLMANN, R .
AMERICAN JOURNAL OF MEDICINE, 1989, 87 (5A) :S98-S102